Several companies have begun exploring trial pathways with Cannvalate’s clinical research arm as they seek to bring Schedule 3 over-the-counter products to Australian consumers.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The Medicinal Cannabis Research Collaboration (MCRC), a joint venture between Cannvalate and a major Melbourne university, said it is supporting five firms in their respective bids to register low-dose CBD medicine with the Therapeutic Goods Administration, including ASX-listed Avecho and New Zealand-based Greenfern Industries.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...